Cullinan Oncology, Inc. filed an amendment to correct the item number in a previous filing, with no other changes made. The company reported unaudited cash, cash equivalents, investments, and interest receivable of $468.3 million as of December 31, 2023, and expects its cash resources to last until the second half of 2026 based on its current operating plan.